These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17826041)

  • 1. Diabetes mellitus and macrovascular disease: mechanisms and mediators.
    Boyle PJ
    Am J Med; 2007 Sep; 120(9 Suppl 2):S12-7. PubMed ID: 17826041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR agonists in the treatment of insulin resistance and associated arterial disease.
    Camejo G
    Int J Clin Pract Suppl; 2003 Mar; (134):36-44. PubMed ID: 12793596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New aspects in the pathogenesis of diabetic atherothrombosis.
    Moreno PR; Fuster V
    J Am Coll Cardiol; 2004 Dec; 44(12):2293-300. PubMed ID: 15607389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
    Tomono Y; Iwai M; Inaba S; Mogi M; Horiuchi M
    Am J Hypertens; 2008 Feb; 21(2):206-12. PubMed ID: 18188158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F; Caglayan E; Hsueh WA
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors responsible for the evolution of insulin resistance in Japanese type 2 diabetic patients: association with atherosclerosis.
    Taniguchi A; Fukushima M; Nakai Y; Kuroe A; Ohya M; Ohgushi M; Seino Y
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S213-9. PubMed ID: 17532086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atherothrombosis in patients with type 2 diabetes mellitus: an overview of pathophysiology].
    Mafrici A; Proietti R
    G Ital Cardiol (Rome); 2010 Jun; 11(6):467-77. PubMed ID: 20922872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance--a common link between type 2 diabetes and cardiovascular disease.
    Lebovitz HE
    Diabetes Obes Metab; 2006 May; 8(3):237-49. PubMed ID: 16634983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
    Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
    Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of insulin resistance on endothelial progenitor cells and vascular repair.
    Cubbon RM; Kahn MB; Wheatcroft SB
    Clin Sci (Lond); 2009 Aug; 117(5):173-90. PubMed ID: 19630751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
    Chung SS; Kim M; Youn BS; Lee NS; Park JW; Lee IK; Lee YS; Kim JB; Cho YM; Lee HK; Park KS
    Mol Cell Biol; 2009 Jan; 29(1):20-30. PubMed ID: 18936159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.